EDAP to Report Fourth Quarter and Full-Year 2014 Results on April 2, 2015
March 17 2015 - 7:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that it plans to release financial
results for the fourth quarter and year ended December 31, 2014 on
Thursday, April 2, 2015, during pre-market hours.
Company management will host a conference call on Thursday,
April 2, 2015 at 8:30 a.m. ET to discuss the results and provide an
update on recent business developments, including its plans to
pursue a Direct De Novo 510(k) petition for Ablatherm HIFU in the
United States. To participate in the call, please dial
1-888-348-6419 in the U.S., or 1-412-902-4235 internationally. The
conference ID number is 10062222. A live webcast of the conference
call will be available on the investor relations page of the
Company's corporate website at www.edap-tms.com.
After the live event, the webcast will remain available on
EDAP's website through May 2, 2015. In addition, a dial-in
replay of the call will be available until April 9, 2015. The
telephone replay can be accessed by calling 1-877-870-5176 in the
U.S. or 1-858-384-5517 internationally. Please use event
passcode 10062222.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer outside
the U.S. HIFU treatment is shown to be a minimally invasive and
effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment. Ablatherm-HIFU is approved for commercial
distribution in Europe and some other countries including Mexico
and Canada. EDAP TMS is currently pursuing a Direct De Novo 510(k)
petition in lieu of a PMA for Ablatherm clearance by the U.S. FDA.
The Company also markets an innovative robot-assisted HIFU device,
the Focal One®, dedicated to focal therapy of prostate cancer.
Focal One® is CE marked but is not FDA approved. The Company also
develops its HIFU technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and distributes
medical equipment (the Sonolith® lithotripters' range) for the
treatment of urinary tract stones using extra-corporeal shockwave
lithotripsy (ESWL) in most countries including Canada and the U.S.
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among others
the uncertainties of the U.S. FDA clearance process, the clinical
status and market acceptance of our HIFU devices and the continued
market potential for our lithotripsy device. Factors that may cause
such a difference also may include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F. Ablatherm-HIFU is not FDA-cleared or
marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2024 to Oct 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Oct 2023 to Oct 2024